Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.77 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.73 |
| ▸ | CTSD | P07339 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234023 | 1.00 | BACE1 (0.77) | BACE1BACE2CTSD | |
| SCHEMBL4913709 | 0.89 | BACE1 (0.61) | BACE1BACE2CTSD | |
| SCHEMBL4509191 | 0.88 | BACE1 (0.77) | BACE1BACE2CTSD | |
| SCHEMBL8237937 | 0.88 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL7941863 | 0.88 | BACE1 (0.60) | BACE1BACE2CTSD | |
| SCHEMBL4913387 | 0.88 | BACE1 (0.59) | BACE1BACE2CTSD | |
| SCHEMBL4912053 | 0.87 | BACE1 (0.58) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL4121222 | 0.87 | BACE1 (0.59) | BACE1BACE2CTSD | |
| SCHEMBL4113083 | 0.86 | BACE1 (0.67) | BACE1BACE2CTSD | |
| SCHEMBL4782043 | 0.85 | BACE1 (0.57) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954682-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER S DISEASE, NEURODEGENERATION AND DEMENTIA | Astra Zeneca AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007058601-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |